The Globe and Mail reports in its Wednesday, Jan. 29, edition that MKM Partners analyst Bill Kirk cut Hexo ($1.73) to "neutral" from "buy" with a share target of $1.50, down from $5. The Globe's David Leeder writes in the Eye On Equities column that analysts on average target the shares at $2.60. On Monday, it was revealed Hexo has been sued by Medipharm Labs for the non-payment of $9.8-million related to shipments of marijuana resin. Mr. Kirk says the failure to pay suppliers adds uncertainty that cannot be offset by its strong Original Stash brand sales and new Quebec retail stores. The Globe reported on Oct. 31, 2019, that Canaccord Genuity analyst Matt Bottomley cut Hexo to "hold" from "speculative buy." As well, he trimmed his share target to $3.50 from $7. Mr. Bottomley said he was disappointed by Hexo's fourth quarter results. The shares could then be had for $2.97. The Globe reported on Jan. 25 that Laurentian Bank Securities analyst Chris Blake lowered his share target for Hexo to $3.25 from $3.50 with a "buy" rating. The shares could then be had for $1.84.